[Nephrology: news in renal transplantation].
The selection of potential living donors will have to consider the latest data on risk factors for morbidity and mortality when a first degree relationship exists with a recipient in end-stage renal disease of unknown, and for women of childbearing age. Renal transplant patients with active hepatitis C of unknow origin will benefit from new antivirals without the risk of acute rejection. Preemptive CYP3A5 genotyping and extended-release tacrolimus formulations should allow the prescription of a suitable dose of tacrolimus immediately and avoid overexposure as a source of nephrotoxicity. The place of everolimus and belatacept in the panel of immunosuppressive treatments is being defined, based on infectious and immunologic risk factors.